The Trump administration has made its most significant move on federal cannabis policy in decades, reclassifying state-licensed medical marijuana from the strictest Schedule I category to the less restrictive Schedule III of the Controlled Substances Act. Acting Attorney General Todd Blanche signed the order last Thursday, acting on a presidential directive issued in December. The change, long sought by advocates and industry, formally acknowledges that cannabis has accepted medical uses and a lower potential for abuse than drugs such as heroin, alongside which it had been classified since 1970. Yet the shift is narrower than it first appears. It does not legalise marijuana at the federal level, nor does it affect the status of recreational cannabis, which remains illegal under national law. The immediate practical consequences are concentrated on the business side: producers in the forty states where medical use is already legal will gain access to standard tax deductions and may see lower barriers to research. For patients, the change is less dramatic; access and prescription remain governed by state law, which varies enormously.

Viewed from Washington, the step is a calibrated political gamble. President Trump, who once suggested he supported states’ rights on cannabis but did little to advance federal reform, has now handed the industry a concrete benefit while stopping short of full legalisation, a move that could alienate his conservative base. The order has not altered enforcement patterns: a Newsweek analysis of arrest data shows that in states where marijuana remains fully illegal, such as Idaho and Texas, the annual number of arrests has barely budged. Canadian observers, through Radio-Canada, note that three-quarters of Americans now live in states where cannabis is legal in some form, yet the federal-state gap continues to produce legal uncertainty for businesses and patients alike. In Buenos Aires, the Noticias Argentinas agency reported the announcement as a sign that even the world’s largest economy is recalibrating its approach to a substance that much of Latin America has already decriminalised for medical use.

The reclassification comes alongside a separate executive order, signed days earlier, that expands federal funding for research into psychedelic substances such as LSD and psilocybin for mental-health treatment. Analysts in London see this as a broader signal: the administration appears willing to revisit the scientific and regulatory status of drugs long considered taboo, even as it declines to embrace full legalisation. Yet the limits of this pragmatism are clear. The medical-cannabis rescheduling does not apply to products derived from recreational cultivation, and it leaves the federal prosecution of such activity untouched. As the Drug Enforcement Administration sets a hearing on the change for June 2026, the debate will shift from the White House to the courts and Congress. The most forward-looking question may be whether this modest administrative move becomes a stepping stone toward more comprehensive reform or a ceiling that contains the industry’s ambitions for years to come.